MedPath

Particle Dynamics Acquires EuroAPI UK Spray Drying Facility to Expand Global CDMO Capabilities

2 months ago2 min read

Key Insights

  • Particle Dynamics has acquired EuroAPI UK Ltd.'s commercial spray drying facility in Haverhill, UK, strengthening its position as a global contract development and manufacturing organization.

  • The Haverhill facility brings over 20 years of spray drying experience, mature quality management systems, and a strong GMP track record to support both clinical and commercial-scale projects.

  • The acquisition addresses growing industry demand for improved bioavailability, solubility and stability of therapeutic compounds through advanced particle engineering technologies.

Particle Dynamics, a global leader in particle processing and delivery technologies, has acquired EuroAPI UK Ltd.'s commercial spray drying facility in Haverhill, UK, in a strategic move to expand its contract development and manufacturing organization (CDMO) capabilities. The acquisition adds significant spray drying expertise and capacity to meet growing industry demand for enhanced drug formulation technologies.

Strategic Expansion of Manufacturing Capabilities

The Haverhill facility represents a significant addition to Particle Dynamics' global network, bringing more than 20 years of spray drying experience and a mature quality management system. The site has maintained an impeccable GMP track record while delivering commercial-scale spray drying services for over two decades.
"The Haverhill site is a hidden gem; an exceptionally well-maintained facility with an experienced team in place, already delivering commercial-scale spray drying for more than two decades," said Nicolas Fortin, CEO of Particle Dynamics. "In addition, the site has an impeccable quality track record."

Addressing Critical Drug Development Challenges

The acquisition positions Particle Dynamics to better serve the pharmaceutical industry's growing need for improved drug formulation technologies. Spray drying technology plays a crucial role in enhancing the bioavailability, solubility, and stability of therapeutic compounds - critical factors in modern drug development.
Fortin emphasized the clinical and commercial significance of the expansion: "I'm delighted that through this acquisition, Particle Dynamics will extend its clinical and commercial offering to help meet the industry's growing demand for improved bioavailability, solubility and stability of therapeutic compounds."

Investment in Future Growth

Particle Dynamics plans to invest in additional capabilities and talent at the Haverhill site, positioning it to serve both clinical and commercial-scale projects. The facility is expected to become a blueprint for operational excellence within the company's global network.
"I'm pleased to welcome Nicholas Hodgson and the Haverhill team to Particle Dynamics," Fortin added. "This site will be a blueprint for operational excellence in our global network."
The acquisition strengthens Particle Dynamics' position in the competitive CDMO market by expanding both its geographic footprint and technical capabilities in particle engineering technologies.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.